
EP 263: Bringing the first cardiovascular gene editing therapy to patients with Sek Kathiresan of Eli Lilly
Notas do episódio
This week on The Genetics Podcast, Patrick is joined by Dr. Sek Kathiresan, CEO of Verve Therapeutics and SVP, Head of Obesity Research and Early Development at Eli Lilly. They discuss how protective genetic variants led to the development of a one-time gene editing therapy for heart disease in the face of early doubt, the phase one results for Verve-102, what recent trial failures mean for genetic target validation, and the unmet needs in obesity treatment.
Show Notes
0:00 Intro to The Genetics Podcast
00:59 Welcome to Sek
01:40 Sek’s family history of heart disease and how it motivated him to pursue cardio therapeutics
03:29 Sek’s background and research on the genetics of coronary artery disease and protective mutations
08:03 Reactions to the Verve launch and the biological, technological, regulatory, and commercial risks
11:00 Verve-102 phase one results and the case for lifelong LDL lowering
16:14 Why cumulative exposure means lowering LDL earlier and for longer
17:53 Recent trial failures in genetically validated targets and what the Lp(a) trial leaves unanswered
20:33 Polygenic risk scores and who benefits most from LDL lowering
23:36 Sek’s new role at Lilly and the remaining unmet needs in obesity treatment
29:06 Whether one-time gene therapy could work for obesity and how GLP-1 drugs drive weight loss
30:38 Food intake, energy expenditure, and the search for new obesity mechanisms
32:15 Why Lilly is investing so heavily in genetic medicine
34:35 Closing remarks
Find out more
ANGPTL3 study in NEJM (https://pmc.ncbi.nlm.nih.gov/articles/PMC3008575/)
Verve-102 study (https://www.nejm.org/doi/10.1056/NEJMoa2601283)